Our patent application, US Patent Application Serial Number 17/137,317, has had all claims allowed by the US Patent and Trademark office. This application covers the method underlying our ADCI Radiation biodosimetry software system. New claims cover partial body exposures, which are typical in radiation therapy. In addition, this invention covers applications of the technology which do not require interaction with the microscope system software, and can be used as a standalone system. The patent should be issued within the next several months.
On May 10, 2021, CytoGnomix is presenting a poster at ConRad 2021 (www.radiation-medicine.de) titled:
Demonstration of the Automated Dicentric Chromosome Identifier and Dose Estimator [ADCI] System in a Cloud-based, Online Environment.
From the abstract:
Interpretation of cytogenetic metaphase images and quantification of exposures remain labour intensive in radiation biodosimetry, despite computer-assisted dicentric chromosome (DC) recognition and strategies to share workloads among different biodosimetry laboratories. ADCI processes the captured images to identify DCs, selects images, and quantifies radiation exposure. This paper describes ADCI_Online, a secure web-streaming platform on Amazon Web Services that can be accessed worldwide from distributed local nodes.
ADCI_Online offers a subscription-based service useful for radiation research, biodosimetry proficiency testing, inter-laboratory comparisons, and training. In a research context, the system could provide highly uniform, reproducible assessment in large studies of many individuals, for example, exposed to therapeutic radiation. ADCI_Online compute environments originate from a single snapshot which can be cloned any number of times; thus, the system can be rapidly scaled when required. With robust network connectivity in a medical emergency of multiple potentially radiation exposed individuals, throughput and capacity for multiple samples requiring simultaneous processing and dose evaluation can be expanded to seamlessly mitigate any backlog in sample interpretation.
Misclassification of patients with underlying disorders by otherwise accurate radiation gene signatures compromises their utility for population-scale radiation exposure assessment. Underlying conditions modify the normal baseline values of biomarkers used for diagnostic analysis of radiation exposure. The collective frequency of these conditions would confound efforts to assess radiation exposures in a mass casualty event, affecting determination of eligibility for radiation-mitigating therapies.
We have published a new article about accelerating biodosimetry testing in a large scale radiation incident:
Rogan PK, Mucaki EJ, Shirley BC, Li Y, Wilkins RC, Norton F, Sevriukova O, Pham N-D, Waller E, Knoll JHM. Automated Cytogenetic Biodosimetry at Population-Scale. Radiation. 2021; 1(2):79-94. doi: 10.3390/radiation1020008 (2021)